BMS-Backed Transition Bio Scores $50M to Mine Biomolecular Condensates for Therapeutic Use

Transition Bio officially debuted Thursday morning with $50 million in Series A financing led by Northpond Ventures with participation from Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures. The company plans to utilize its microfluidics-driven drug discovery platform and AI tools to map and modulate biomolecular condensates.